Relationship Between P53 Status and Response to Chemotherapy in Patients with Gastric Cancer: a Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Apr 18

PMID 24740294

Citations 18

Authors

Hai-Yuan Xu

Wen-Lin Xu

Li-Qiang Wang

Min-Bin Chen

Hui-Ling Shen

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies have yielded conflicting results regarding the relationship between p53 status and response to chemotherapy in patients with gastric cancer. We therefore performed a meta-analysis to expound the relationship between p53 status and response to chemotherapy.

Methods/findings: Thirteen previously published eligible studies, including 564 cases, were identified and included in this meta-analysis. p53 positive status (high expression of p53 protein and/or a mutant p53 gene) was associated with improved response in gastric cancer patients who received chemotherapy (good response: risk ratio [RR] = 0.704; 95% confidence intervals [CI] = 0.550-0.903; P = 0.006). In further stratified analyses, association with a good response remained in the East Asian population (RR = 0.657; 95% CI = 0.488-0.884; P = 0.005), while in the European subgroup, patients with p53 positive status tended to have a good response to chemotherapy, although this did not reach statistical significance (RR = 0.828, 95% CI = 0.525-1.305; P = 0.417). As five studies used neoadjuvant chemotherapy (NCT) and one used neoadjuvant chemoradiotherapy (NCRT), we also analyzed these data, and found that p53 positive status was associated with a good response in gastric cancer patients who received chemotherapy-based neoadjuvant treatment (RR = 0.675, 95% CI = 0.463-0.985; P = 0.042).

Conclusion: This meta-analysis indicated that p53 status may be a useful predictive biomarker for response to chemotherapy in gastric cancer. Further prospective studies with larger sample sizes and better study designs are required to confirm our findings.

Citing Articles

Molecular Classifications in Gastric Cancer: A Call for Interdisciplinary Collaboration.

Diaz Del Arco C, Fernandez Acenero M, Ortega Medina L Int J Mol Sci. 2024; 25(5).

PMID: 38473896 PMC: 10931799. DOI: 10.3390/ijms25052649.

Replicative stress in gastroesophageal cancer is associated with chromosomal instability and sensitivity to DNA damage response inhibitors.

Sahgal P, Patil D, Bala P, Sztupinszki Z, Tisza V, Spisak S iScience. 2023; 26(11):108169.

PMID: 37965133 PMC: 10641495. DOI: 10.1016/j.isci.2023.108169.

The critical role of circular RNAs in drug resistance in gastrointestinal cancers.

Tehrani S, Esmaeili F, Shirzad M, Goodarzi G, Yousefi T, Maniati M Med Oncol. 2023; 40(4):116.

PMID: 36917431 DOI: 10.1007/s12032-023-01980-4.

TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.

Erazo T, Evans C, Zakheim D, Chu E, Refermat A, Asgari Z Nat Commun. 2022; 13(1):5676.

PMID: 36167829 PMC: 9515221. DOI: 10.1038/s41467-022-33137-8.

Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status.

Wood A, Zhang Y, Mo Q, Cen L, Fontaine J, Hoffe S Oncologist. 2022; 27(4):307-313.

PMID: 35380714 PMC: 8982441. DOI: 10.1093/oncolo/oyac018.

References

Nakata B, Chung K, Ogawa M, Ogawa Y, Yanagawa K, Muguruma K . p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer. Surg Today. 1998; 28(6):595-8. DOI: 10.1007/s005950050190. View

Lamb P, Crawford L . Characterization of the human p53 gene. Mol Cell Biol. 1986; 6(5):1379-85. PMC: 367661. DOI: 10.1128/mcb.6.5.1379-1385.1986. View

Fareed K, Al-Attar A, Soomro I, Kaye P, Patel J, Lobo D . Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer. 2010; 102(11):1600-7. PMC: 2883154. DOI: 10.1038/sj.bjc.6605686. View

Bataille F, Rummele P, Dietmaier W, Gaag D, Klebl F, Reichle A . Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. Mol Pathol. 2003; 56(5):286-92. PMC: 1187340. DOI: 10.1136/mp.56.5.286. View

Giatromanolaki A, Stathopoulos G, Koukourakis M, Rigatos S, Vrettou E, Kittas C . Angiogenesis and apoptosis-related protein (p53, bcl-2, and bax) expression versus response of gastric adenocarcinomas to paclitaxel and carboplatin chemotherapy. Am J Clin Oncol. 2001; 24(3):222-6. DOI: 10.1097/00000421-200106000-00002. View

Vousden K, Prives C . Blinded by the Light: The Growing Complexity of p53. Cell. 2009; 137(3):413-31. DOI: 10.1016/j.cell.2009.04.037. View

Yeh K, Shun C, Chen C, Lin J, Lee W, Lee P . Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy. Hepatogastroenterology. 1999; 46(25):610-5. View

Boku N, Ohtsu A, Yoshida S, Shirao K, Shimada Y, Hyodo I . Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. Jpn J Clin Oncol. 2007; 37(4):275-81. DOI: 10.1093/jjco/hym015. View

Qu J, Shi Y, Hao F . [Clinical study of the predictors to neoadjuvant chemotherapy in patients with advanced gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. 2013; 16(3):276-80. View

10.

Cascinu S, Graziano F, Del Ferro E, Staccioli M, Ligi M, Carnevali A . Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer. 1998; 83(9):1917-22. View

11.

Mezhir J, Tang L, Coit D . Neoadjuvant therapy of locally advanced gastric cancer. J Surg Oncol. 2010; 101(4):305-14. DOI: 10.1002/jso.21483. View

12.

Nashimoto A, Yabusaki H, Tanaka O, Sasaki J, Akiyama N . Neoadjuvant chemotherapy in advanced gastric cancer with non-curative factors: a Phase II study with 5-fluorouracil, leucovorin, and cisplatin. Gastric Cancer. 2002; 2(1):57-63. DOI: 10.1007/s101200050022. View

13.

Weller M . Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res. 1998; 292(3):435-45. DOI: 10.1007/s004410051072. View

14.

Pakos E, Kyzas P, Ioannidis J . Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis. Clin Cancer Res. 2004; 10(18 Pt 1):6208-14. DOI: 10.1158/1078-0432.CCR-04-0246. View

15.

Lowe S, Bodis S, McClatchey A, Remington L, Ruley H, Fisher D . p53 status and the efficacy of cancer therapy in vivo. Science. 1994; 266(5186):807-10. DOI: 10.1126/science.7973635. View

16.

Sirak I, Petera J, Hatlova J, Vosmik M, Melichar B, Dvorak J . Expression of p53, p21 and p16 does not correlate with response to preoperative chemoradiation in gastric carcinoma. Hepatogastroenterology. 2009; 56(93):1213-8. View

17.

Kamangar F, Dores G, Anderson W . Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24(14):2137-50. DOI: 10.1200/JCO.2005.05.2308. View

18.

Lowe S, Ruley H, Jacks T, Housman D . p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993; 74(6):957-67. DOI: 10.1016/0092-8674(93)90719-7. View

19.

Nagashima F, Boku N, Ohtsu A, Yoshida S, Hasebe T, Ochiai A . Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin. Jpn J Clin Oncol. 2005; 35(12):714-9. DOI: 10.1093/jjco/hyi194. View

20.

Ott K, Sendler A, Becker K, Dittler H, Helmberger H, Busch R . Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer. 2003; 6(3):159-67. DOI: 10.1007/s10120-003-0245-4. View